Natco Pharma rose 1.52% to Rs 1,013.65 at 11:50 IST on BSE after the company announced the receipt of successful Establishment Inspection Report from the US drug regulator after inspection for its Kothur facility.
The announcement was made during market hours today, 20 July 2017.Meanwhile, the S&P BSE Sensex was up 11.68 points or 0.04% at 31,967.03.
On the BSE, 35,047 shares were traded on the counter so far as against the average daily volumes of 55,893 shares in the past one quarter. The stock had hit a high of Rs 1,027.45 and a low of Rs 1,000 so far during the day. The stock had hit a record high of Rs 1,080 on 9 June 2017 and a 52-week low of Rs 495 on 9 November 2016.
The stock had underperformed the market over the past one month till 19 July 2017, gaining 1.99% compared with Sensex's 2.06% rise. The scrip had also underperformed the market in past one quarter, rising 3.55% as against Sensex's 8.93% rise. The scrip had, however, outperformed the market in past one year, gaining 70.57% as against Sensex's 15% rise.
The large-cap company has equity capital of Rs 34.86 crore. Face value per share is Rs 2.
Natco Pharma announced the receipt of successful Establishment Inspection Report (EIR) from the US Food and Drug Administration (USFDA) for the inspection conducted at its drug formulations facility at Kothur unit, Telangana, India, during the period 16 to 24 January 2017.
Kothur formulation facility predominantly caters to regulated international markets, including USA.
More From This Section
Natco Pharma's consolidated net profit spurted 181.4% to Rs 176.70 crore on 46.5% increase in net sales to Rs 577.80 crore in Q4 March 2017 over Q4 March 2016.
Natco Pharma manufactures generic dosage forms, bulk actives and intermediates for the Indian and international markets.
Powered by Capital Market - Live News